Nantes, France-based biotech OSE Immunotherapeutics (Euronext: OSE) has agreed a deal with immuno-oncology diagnostic firm HalioDx, to conduct a translational investigation of immune biomarkers.
The collaboration will help support ongoing development of the neoepitope combination Tedopi, formerly known as OSE-2101, in non-small cell lung cancer (NSCLC).
Tedopi is currently being evaluated in the Phase III Atalante 1 trial in advanced NSCLC.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze